Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 8:28 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 2,510 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: RAPID Clear all

Conditions: Congenital Heart Disease
Interventions: RAPID; Device
Lead sponsor: University of Minnesota; Other
Eligibility: Up to 1 Year
Enrollment: 22 participants
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Healthy Participants
Interventions: Plixorafenib, Cobicistat; Drug
Lead sponsor: Fore Biotherapeutics; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 28 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Hematopoietic Stem Cell Transplantation, Graft Failure
Interventions: Emapalumab 3 mg/kg, Emapalumab 10 mg/kg; Drug
Lead sponsor: Children's Hospital Medical Center, Cincinnati; Other
Eligibility: Not listed
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Neurofibromatosis Type 1 (NF1)-Related Plexiform Neurofibromas (PNs), Healthy Participants
Interventions: Treatment A, Treatment B, Treatment C, Treatment D, Acetaminophen; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 45 Years · Male only
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Tobacco Dependence
Interventions: Usual care, Lung age, Contingency Management, Lung age + Contingency Management; Behavioral
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Healthy Subjects
Interventions: Ziresovir, Placebo; Drug · Other
Lead sponsor: Shanghai Ark Biopharmaceutical Co., Ltd.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021
U.S. locations: 1
States / cities: Secaucus, New Jersey

Conditions: CF - Cystic Fibrosis, Cystic Fibrosis-related Diabetes, Cystic Fibrosis Liver Disease
Interventions: Fibroscan; Device
Lead sponsor: Dartmouth-Hitchcock Medical Center; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Lebanon, New Hampshire

Conditions: Acute Kidney Injury
Interventions: Not listed
Lead sponsor: Abbott RDx Cardiometabolic; Other
Eligibility: 21 Years and older
Enrollment: 1,001 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 25
States / cities: Los Angeles, California • San Diego, California • San Francisco, California + 21 more

Conditions: Drug Drug Interaction
Interventions: Pirfenidone 267 mg Oral Tablet, Nintedanib 150 mg Oral Capsule, BLD-0409 750 mg Oral Tablet; Drug
Lead sponsor: Blade Therapeutics; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 86 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Chlamydia Trachomatis Infection, Neisseria Gonorrheae Infection, Asymptomatic Condition
Interventions: ID NOW™; Diagnostic Test
Lead sponsor: Abbott Rapid Dx; Industry
Eligibility: 14 Years and older
Enrollment: 7,100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: New Orleans, Louisiana

Conditions: Posttraumatic Stress Disorder (PTSD)
Interventions: Vocational Rehabilitation Program (VRP), Individual Placement and Support (IPS); Behavioral
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 19 Years to 60 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2012
U.S. locations: 1
States / cities: Tuscaloosa, Alabama

Conditions: Bipolar Disorder
Interventions: Lithium Plus Extended- Release Carbamazepine; Drug
Lead sponsor: Creighton University; Other
Eligibility: 19 Years to 65 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 1
States / cities: Omaha, Nebraska

Conditions: Healthy
Interventions: CHR-2797; Drug
Lead sponsor: CTI BioPharma; Industry
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012
U.S. locations: 1
States / cities: Evansville, Indiana

Conditions: Healthy Participants
Interventions: Lorcaserin manufactured at Zofingen, Lorcaserin manufactured at Kawashima; Drug
Lead sponsor: Eisai Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Prostatic Hyperplasia
Interventions: Treatment sequence A, Treatment sequence B, Treatment sequence C, Treatment sequence D; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 45 Years · Male only
Enrollment: 81 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2008
U.S. locations: 2
States / cities: Evansville, Indiana • Austin, Texas

Conditions: Diabetes, Diabetes Mellitus, Type 2
Interventions: Faster-acting insulin aspart, Insulin aspart, Insulin degludec, Metformin; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years and older
Enrollment: 1,264 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 64
States / cities: Concord, California • Fresno, California • Fullerton, California + 56 more

Conditions: Congenital Cystic Kidney Disease
Interventions: Venglustat GZ402671; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021
U.S. locations: 1
States / cities: Morgantown, West Virginia

Conditions: Substance Abuse, Intravenous
Interventions: Abstinence-contingent wage supplements, Individual Placement and Support (IPS) supported employment; Behavioral
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years and older
Enrollment: 91 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Type 2 Diabetes
Interventions: Hepatic Ultrasound Insonification; Device
Lead sponsor: General Electric Research; Industry
Eligibility: 21 Years to 75 Years
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Chula Vista, California

Conditions: Healthy
Interventions: BG00012 (dimethyl fumarate), BG00012 placebo, ASA, ASA placebo; Drug
Lead sponsor: Biogen; Industry
Eligibility: 25 Years to 55 Years
Enrollment: 173 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012
U.S. locations: 1
States / cities: Saint Paul, Minnesota

Conditions: Adenomatous Polyps
Interventions: Walking; Behavioral
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 50 Years to 80 Years
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Healthy
Interventions: quick Contrast Sensitivity Function test; Other
Lead sponsor: Nova Southeastern University; Other
Eligibility: 20 Years to 89 Years
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Fort Lauderdale, Florida

Conditions: Heart Failure
Interventions: Not listed
Lead sponsor: Boston Scientific Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 891 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 1
States / cities: New Hyde Park, New York

Conditions: Parathyroid; Anomaly, Parathyroid Dysfunction, Hyperparathyroidism, Parathyroid Gland Adenoma
Interventions: Parakeet:The Parakeet Rapid Parathyroid Testing Kit is a rapid immunoassay designed to detect Parathormone (PTH) in a test sample.; Device
Lead sponsor: Neurovision Medical Products Inc; Industry
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Ventura, California

Search by objective public record fields.

RAPID: a Comparison Study of a Novel Ultrasound Device of Automated Congenital Heart Imaging

A Study of the Effects of Food and Cobicistat on Plixorafenib Pharmacokinetics in Healthy Participants.

Prevention of Graft Rejection in Hematopoietic Stem Cell Transplant (HSCT) Recipients

A Study to Evaluate Bioavailability and Food Effect of Selumetinib (AZD6244) in Healthy Male Participants

A Study of Novel Smoking Cessation Interventions in Current and Former Injection Drug Users

A Study Evaluating the Safety, Tolerability, and Pharmacokinetics of Ziresovir in Healthy Subjects

Relationship Between the Development of Impaired Glucose Tolerance, the Phenotype of CFLD, and the Risk of Liver Fibrosis

Rapid Evaluation of Acute Kidney Injury With NGAL in Acutely Ill Patients in the ICU

Dedicated Drug-Drug Interaction (DDI) Study in Healthy Volunteers

Clinical Evaluation of the ID NOW™ CT/NG Test

The Impact of Vocational Rehabilitation on Mentally III Veterans

Open Label Study of Lithium Plus Extended-Release Carbamazepine (ERC-CBZ) for Rapid Cycling Bipolar Disorder

Crossover Trial of the Effect of a High-Fat Meal on the PK of Oral CHR 2797 in Healthy Male Subjects

A Study to Demonstrate Bioequivalence Between Lorcaserin Extended Release (XR) Tablets Manufactured in Kawashima and Lorcaserin XR Tablets Manufactured in Zofingen in Healthy Participants

A Study To Compare Giving AVODART And FLOMAX Together Or In A Combination Capsule In The Fed And Fasted State

Research Study Comparing a New Medicine "Fast-acting Insulin Aspart" to Another Already Available Medicine "NovoRapid"/"NovoLog" in People With Type 2 Diabetes

Long-term Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD) With Venglustat

The Long-Term Treatment of Drug Addiction and Unemployment

Pilot Study to Assess the Effects of Hepatic Ultrasound Insonification on Subjects With T2DM

Effect of Aspirin Pretreatment or Slow Dose Titration on Flushing and Gastrointestinal Events in Healthy Volunteers Receiving Delayed-release Dimethyl Fumarate

Step Down Colon Cancer Risk

Test-Retest Variability of Quick Contrast Sensitivity Function Testing

RAPID-RF: Remote Active Monitoring in Patients With Heart Failure

STP.168 Clinical Study Protocol Parakeet